Thor Medical
Thor Medical ASA is a Norwegian clinical-stage radiopharmaceutical technology company developing alpha emitters for targeted cancer therapy. The company utilizes proprietary extraction technology to produce thorium-228 and radium-224 isotopes from natural thorium for use in targeted radionuclide therapies. Main revenue drivers currently comprise development partnerships, isotope supply agreements, and capital markets financing as production technology scales. Thor Medical targets radiopharmaceutical developers, biopharmaceutical companies, and clinical research institutions globally. The company holds a specialized niche position in raw material production for next-generation alpha-emitting radiotherapeutics. Headquartered in Oslo, Norway, Thor Medical ASA is listed on Oslo Bors.
6 of the funds FundTelligence covers report a position in Thor Medical.
- Legal name
- Thor Medical ASA
- Sector
- Health Care
- Country
- Norway
- Funds holding it
- 6
Funds holding Thor Medical
- Danske Invest Norge Vekst — Danske Invest · 0.92 % (full portfolio disclosed, September 2026)
- Danske Invest Norway Index Restricted — Danske Invest · 0.06 % (full portfolio disclosed, September 2026)
- KLP AksjeNorge Indeks — KLP · 0.05 % (full portfolio disclosed, June 2026)
- Storebrand Indeks Norge — Storebrand · 0.05 % (full portfolio disclosed, October 2026)
- DNB Norge Indeks — DNB · 0.05 % (full portfolio disclosed, September 2026)
- Handelsbanken Norden Index Criteria — Handelsbanken · 0.05 % (full portfolio disclosed, October 2026)